Kefazol is commonly used to address susceptible bacterial infections and manage infection risk in specific clinical scenarios. It is applied in conditions marked by increased physiological stress, such as septicemia, pneumonia, bone and joint infections, and serious skin and soft tissue infections.

It is also commonly used for managing infection risk in the perioperative setting, and is applied in scenarios where additional management of discomfort is required, such as surrounding certain high-risk procedures. This use provides supportive relief by addressing the presence of potential pathogens, which assists with maintaining functional stability during recovery.

Kefazol is applied in addressing symptoms that interfere with daily functioning and those related to systemic imbalance. It supports the management of symptoms related to physical discomfort, such as localized pain and swelling, and may assist with easing the overall symptom load, including high fever and malaise.

“The primary goal is to provide supportive relief during the infectious process, helping patients cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Localized Inflammation Kefazol is used to address symptoms like redness, swelling, and pain that cluster together at the site of a severe bacterial infection.

Regulatory References

1. NIH DailyMed Official Label

Who Can and Cannot Use Kefazol?

Kefazol (Cefazolin) eligibility is defined by regulatory documents, distinguishing between populations that are permitted, restricted, or contraindicated from using the medicine.

Contraindicated Populations

The medicine is absolutely contraindicated for patients with a documented history of hypersensitivity (allergy) to Cefazolin itself, or to any antibiotic in the cephalosporin, penicillin, or other beta-lactam class.

Age and Physiological Restrictions

Use is not recommended in premature infants and infants under 1 month of age (neonates), as the safety of Cefazolin in this age group has not been fully established. Use is generally established for adults and pediatric patients starting from one month of age.

Conditional Use Requirements

Eligibility is conditional for certain populations, often requiring careful monitoring:

• Renal Impairment: Patients with decreased kidney function (e.g., Creatinine Clearance less than 55 mL/min) are eligible but require dosage adjustment as defined in the prescribing information.
• Pregnancy and Lactation: Cefazolin is classified as FDA Pregnancy Category B. Use is conditional and should only occur if the potential benefit is clearly needed. Low levels of the drug are present in breast milk, and use is generally considered acceptable.
• Comorbidities: Use is advised with caution in patients with a history of gastrointestinal disease, particularly colitis, and in those with a history of seizure disorders.

Interactions with other medicines and products

The official regulatory profile for Cefazolin sodium (Kefazol) details specific pharmacokinetic and pharmacodynamic interactions with other medicinal products and laboratory procedures. These patterns describe how the drug's activity or concentration is modified, necessitating restrictions or monitoring.

---

The co-administration of Probenecid is not recommended due to a documented pharmacokinetic interaction. Probenecid inhibits the renal tubular secretion of Cefazolin, a transporter-mediated effect that results in increased and more prolonged Cefazolin plasma concentrations. This heightened exposure forms the regulatory basis for restricting co-use of these two substances.

---

A pharmacodynamic interaction exists with Oral Anticoagulants, such as Warfarin, as the combination is associated with a fall in prothrombin activity. This effect mandates the monitoring of coagulation status. Similarly, use with other known nephrotoxic agents, including certain aminoglycosides, is associated with an increased risk of nephrotoxicity through an additive effect.

---

Patients with impaired renal function are noted to have reduced clearance of Cefazolin, which leads to prolonged plasma concentrations and is the regulatory rationale for potential neurotoxicity. Separately, Cefazolin may cause a false positive reaction for glucose in the urine when tests utilize non-enzymatic reagents, such as Benedict’s solution or CLINITEST tablets.

Irreversible Blockade of Bacterial Cell Wall Construction

Kefazol's action is defined by its ability to covalently and permanently inhibit key enzymes known as Penicillin-Binding Proteins (PBPs) in the bacterial cell wall. This specific blockade prevents the final cross-linking step of the structural polymer, peptidoglycan, resulting in a synthesized bacterial cell envelope that lacks structural integrity.

---

Causal Cascade Leading to Microbial Cell Lysis

The structural failure induced by PBP inhibition results in an osmotic imbalance within the bacterium that exceeds the capacity of the compromised wall. This mechanical stress, combined with the activation of microbial autolytic enzymes, triggers the cell to rupture (lysis) and die. This definitive bactericidal action is the primary physiological consequence, resulting in the elimination of viable bacterial cells.

---

Limitations Imposed by Bacterial Resistance

The mechanism's activity is biologically constrained by adaptive microbial defenses. Bacteria that produce beta-lactamase enzymes can chemically neutralize the drug before it reaches the target. Furthermore, strains that acquire altered PBPs exhibit reduced drug affinity, functionally negating the core inhibitory mechanism and defining the biological limits of the mechanistic action.

Administration and Dosing of Kefazol (Cefazolin)

Kefazol, which contains the active ingredient Cefazolin, is used strictly through parenteral administration—delivered directly into the body via injection, typically intravenously (IV) or intramuscularly (IM). The drug is supplied as a sterile powder that requires careful reconstitution and dilution with an approved solution prior to use. For treatment, IV doses are commonly administered over a period of 30 to 60 minutes to ensure proper delivery.

---

Standard Regimens and Frequency

The standard adult dosing for systemic infections varies by severity. For moderate to severe infections, a common regimen involves administering 500 mg to 1 g every 6 to 8 hours (q6h or q8h). For severe, life-threatening conditions like septicemia, higher doses of 1 g to 1.5 g may be administered every 6 hours. The duration of therapy depends on the condition, but for specific infections caused by beta-haemolytic streptococci, the standard course of treatment must continue for a minimum of 10 days.

---

Key Contextual Instructions

Context	General Guideline
Surgical Prophylaxis	A single dose of 1 g to 2 g must be administered 30 to 60 minutes prior to incision.
Renal Impairment	Dose adjustment is required in adults with creatinine clearance below 55 mL/min to prevent drug accumulation.
Pediatric Use	Dosing for children over one month of age is calculated based on body weight, typically administered in 3 to 4 divided doses daily.

---

These parameters structure the correct procedural use of the medicine, dictating the method of delivery, the precise timing for surgical use, and necessary dose modifications based on kidney function.

Research Evidence / Overview of studies for Kefazol

Evidence for Preventing Infection During Procedures (Surgical Prophylaxis)

The research into Kefazol's (Cefazolin sodium's) role in preventing infection includes numerous studies, primarily consisting of Randomized Controlled Trials (RCTs), supported by large Systematic Reviews and Meta-analyses. These studies were used in research exploring how to measure infection rates, specifically Surgical Site Infections (SSIs), during and immediately after medical procedures across a range of surgical disciplines.

Researchers monitored outcomes related to infectious morbidity by measuring the rate of SSIs and tracking the subsequent length of time patients remained hospitalized. The study designs available for this indication are generally well-established. Studies reported measurements of infection rates, which were observed in populations receiving Cefazolin. Comparative evidence against newer, broader-spectrum agents remains limited or heterogeneous in some trials.

---

Evidence for Treating Serious Systemic Infections

Research focused on Kefazol for treating serious, established infections—such as septicemia (bloodstream infection) and infections of the bone and joints—is mainly derived from Observational Cohort Studies and some Phase IV Non-inferiority Trials. These research settings evaluated outcomes reflecting systemic or functional imbalance by monitoring patient status, including clinical response (measurements of symptom evolution) and measurements of 30-day and 90-day mortality.

For treating serious bloodstream infections caused by Methicillin-Susceptible Staphylococcus aureus (MSSA), data show patterns related to Cefazolin's use compared to other anti-staphylococcal antibiotics. The study designs available for these indications are generally recognized as moderate-level evidence. Randomized data are still emerging for some serious infections, meaning much of the current understanding relies on observational data.

---

⏱️ Durability and Long-Term Follow-up Data

Follow-up durations vary depending on the indication studied. For infection prevention in non-orthopedic surgeries, follow-up durations were often limited to the short-term (typically 30 days post-procedure). However, in specific areas like prosthetic joint surgery, studies have monitored outcomes over long-term periods, sometimes extending to five years or more, to explore long-term infection-related outcomes. Long-term effects are not fully established regarding the sustained absence of infection for more routine acute infections.

Key Studies & References

1. Meta-Analysis of Clinical Trials Comparing Cefazolin to Cefuroxime, Ceftriaxone, and Cefamandole for Surgical Site Infection Prevention
2. Cefazolin - Electronic Essential Medicines List (eEML) - WHO

Common questions about Kefazol (FAQ)

Q: Where should I store Drug X and for how long after I open it?

Official regulatory documents state that Kefazol should be stored at controlled room temperature, typically between 68 F and 77 F (20 C and 25 C). It is important to protect the medicine from moisture and excessive heat. The specific shelf life or stability after the package is opened or reconstituted is typically detailed in the official product information provided.

---

Q: Can I drink alcohol while I am taking Drug X?

The official product information for Kefazol notes that consuming alcohol may increase the risk of certain side effects, such as drowsiness or dizziness, which are listed in the drug's safety profile. Patients should review the official labeling for specific warnings regarding alcohol use.

---

Q: Does Drug X make you feel sleepy or tired?

Feeling tired (fatigue) and sleepy (somnolence) are listed as potential side effects in the official drug information. Due to these possible effects, the official labeling suggests that patients use caution when driving or operating machinery until they understand the medicine's effects.

---

Q: Can I take Drug X if I have kidney disease?

The official prescribing information for Kefazol includes specific guidance regarding its use in patients with renal impairment (kidney disease). This guidance details whether dose adjustments are necessary or if the medicine may be contraindicated (not recommended for use) in certain conditions. This information should be reviewed by a healthcare professional based on the individual patient's specific condition.

---

Q: What happens if I miss a dose of Drug X?

Instructions for a missed dose are outlined in the patient information leaflet that comes with Kefazol. The typical recommendation is that if you realize a dose has been missed, you should consult the leaflet for specific guidance on how to proceed. The product information generally cautions against taking a double dose to compensate for a missed dose.

---

Q: Can pregnant women use Drug X?

Regulatory documents contain data on the use of Kefazol during pregnancy and lactation (breastfeeding). The official labeling provides a summary of the known risks and benefits. Decisions regarding the use of Kefazol during pregnancy or breastfeeding should be made in consultation with a healthcare provider after carefully assessing the potential effects.

How to Store and Dispose of Kefazol (Cefazolin Sodium)

The storage and disposal of Kefazol (cefazolin sodium) must follow specific regulatory requirements to maintain product stability and ensure safety.

---

Storage Requirements

The unreconstituted powder must be stored at Controlled Room Temperature (20 C to 25 C) and protected from light in its original container.

Once reconstituted, the solution is stable for 24 hours at room temperature or up to 10 days under refrigeration. The solution should not be frozen. If the reconstituted fluid contains particulate matter, it must be discarded. As with all medicines, Kefazol must be kept out of the sight and reach of children.

---

Disposal Instructions

Any unused solution from a bulk package must be discarded after 4 hours from initial entry. Disposal of expired or unused cefazolin and its packaging must comply with state and local environmental regulations for drug waste.